Literature DB >> 7878706

Phenytoin and plasmapheresis: importance of sampling times and impact of obesity.

K M Olsen1, M A Marx, M S Monaghan, E Barnes, B H Ackerman, A A Pappas.   

Abstract

The effect of plasmapheresis (PP) on total and free phenytoin clearance is reported. An obese patient with the diagnosis of thrombotic thrombocytopenic purpura (TTP) was treated with PP. Twelve episodes of PP, having exchange volumes of 1.5-2.25 times the plasma volume with a mean +/- SD 7.7 +/- 0.8 L of plasma removed, were studied. A significant (p < 0.05) difference was observed with a mean change in plasma phenytoin concentrations from pre- to end-PP of 7.32 +/- 2.5 mg/L compared to 1.98 +/- 0.7 mg/L observed pre-PP to 1 h post-PP. These values corresponded to 48.4 +/- 11.6 and 15.0 +/- 6.7% decreases in phenytoin concentrations at the two aforementioned time periods. To prevent misinterpretation of plasma phenytoin concentrations, samples should not be obtained for at least 2 h after PP.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7878706

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  4 in total

Review 1.  Effects of obesity on pharmacokinetics implications for drug therapy.

Authors:  G Cheymol
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

2.  Body mass index and weight gain as alternative or complementary hypothesis to explain olanzapine concentration-dose ratio accumulation.

Authors:  Bruno Charpiat
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

Review 3.  Drug-Nutrition Interactions and the Brain: It's Not All in Your Head.

Authors:  Joseph I Boullata
Journal:  Curr Nutr Rep       Date:  2019-06

Review 4.  Drug Dosing in Patients Undergoing Therapeutic Plasma Exchange.

Authors:  Sherif Hanafy Mahmoud; Jessica Buhler; Eric Chu; Suzie A Chen; Theresa Human
Journal:  Neurocrit Care       Date:  2021-02       Impact factor: 3.210

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.